NMPA Approval

Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection

Approval Number

国药准字S20150005

Company杭州博之锐生物制药有限公司

Registration Date

September 3, 2024

Drug Information

Generic Name

注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白

Dosage Form

注射剂

Strength

12.5mg/瓶,生物学活性为1.25×10^6AU/瓶

Drug Type

生物制品

Registration Date

September 3, 2024

Company Information

Applicant Company

Company Name杭州博之锐生物制药有限公司

Company Address

浙江省杭州市富阳区胥口镇海正路8号

Manufacturing Company

Company Name杭州博之锐生物制药有限公司

Company Address

浙江省杭州市富阳区胥口镇海正路8号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 - NMPA 批准文号 | MedPath